 HAYWARD, Calif., Aug. 30, 2021 PRNewswire -- AcelRx Pharmaceuticals, Inc. Nasdaq: ACRX, AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the results of a study evaluating sufentanil sublingual tablet 30 mcg SST for outpatient plastic surgery that was presented during the Miami Cosmetic Surgery MCS conference on Friday, August 27 th at the Miami Beach Convention Center in Miami Beach, Florida. 